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1. INTRODUCTION
1.1 Need for Colorectal Cancer Treatment
Cancer is the second leading cause of death of people ages 1-85 in the United States today, and
the number of new cases is expected to rise by 70% over the next two decades (Organization, 2017). Of
the 8.8 million worldwide cancer deaths in 2015, colorectal cancer accounted for 774,000 of the deaths.
The need for effective colorectal cancer treatment is present through these statistics and is growing in
urgency. Development of these life-saving colorectal cancer treatment and prevention techniques are
dependent on innovative research.
1.2 Colorectal Cancer and Metabolism
Cancer is now accepted as a metabolic disease, where changes in energy metabolism in the
cancer cell promote its progression, development, and metastasis (Seyfried et al., 2014). Identifying the
factors that impact changes in metabolism during progression of colorectal cancer is pivotal. Pyruvate
kinase is a protein that catalyzes the rate limiting, final step of glycolysis to convert
phosphoenolpyruvate to pyruvate by addition of a phosphate group, yielding one pyruvate and one
molecule of ATP (Gupta and Bamezai, 2010). This step is vital for cell growth and survival. It has been
shown that pyruvate kinase exists in four isozymic forms, and that pyruvate kinase M2 (PKM2) is
upregulated in colorectal cancer (Wong et al., 2015). PKM2, a 58-60 kDa member of the PK enzyme
family, is believed to promote the transformation toward glucose-driven cancer cell metabolism and
support cancer cell progression (Dong et al., 2016; Luo and Semenza, 2012; Wong et al., 2015). If the
mechanism of this transformation could be regulated or manipulated, it could serve as a therapeutic
cancer treatment in the future.

3

1.3 Changes in Butyrate Oxidation
Non-cancerous colorectal cells (colonocytes) utilize a bacterial product called butyrate as their
primary energetic source through oxidation (Goncalves and Martel, 2013). Butyrate is a short chain fatty
acid derived from dietary fiber and is produced by resident microbiota in the colon. In contrast,
colorectal cancer cells shift from utilizing butyrate to instead using glucose which is known as the
Warburg effect (Donohoe et al., 2012; Goncalves and Martel, 2013). As colorectal cancer tumors reach
later stages and progress towards metastasis, glucose uptake is increased exponentially in order to
sustain the rapid growth.
1.4 Purpose of Research
These metabolic changes and the shift away from butyrate utilization in colorectal cancer cells
are likely driven by increased expression of PKM2, but it has yet to be demonstrated. This has created
new questions regarding manipulation techniques to effect cancer progression. Specifically, it was
hypothesized that the presence or absence of PKM2 effects the oxidative fate of butyrate in colorectal
cancer cells. While butyrate may encourage the growth of normal colonocytes because it functions as an
oxidative source, via β-oxidation and tricarboxylic acid cycle, it cannot be used efficiently when the
Warburg effect is occurring. Therefore, colorectal cancer cells cannot oxidize butyrate to use as an
energy source and it may inhibit growth of cells. In contrast, colorectal cancer cells that lack PKM2 and
lack the Warburg effect should be able to better oxidize butyrate as an energy source and should not
exhibit cancerous growth patterns, as demonstrated in Figure 1. To support these hypotheses,
characterizations of the metabolism of butyrate in both colorectal cancer cells containing and lacking
PKM2 were performed.
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Figure 1: Proposed shift in butyrate metabolism and proliferation driven by expression of pyruvate kinase M2
(PKM2) in colorectal cancer cells.

2. EXPERIMENTAL PROCEDURES
2.1 Reagents
DMEM, penicillin/streptomycin, puromycin, ammonium persulfate, fetal bovine serum, trypsin,
pyruvate kinase M2 antibodies, β-actin antibodies, agarose gel for electrophoresis, various buffers.
2.2 Cell Culture and Treatment Conditions
HCT 116 cells (ATCC, CCL-247) were grown in DMEM prepared with 5mM glucose and 10%
FBS. HCT 116 PKM2 mRNA scramble cells and HCT 116 PKM2 Knockout cells were grown in
DMEM prepared with 5mM glucose, 10% FBS, and 1 μg/ml Puromycin.
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2.3 Western Blotting
Proteins from the three HCT116 cell types were extracted using RIPA buffer. Bradford assay
was used to measure protein concentration. Standard Western blot protocol was used in gel
electrophoresis and blotting transfer experiments. Antibodies used in this experiment were β-actin and
PKM2.
2.4 Flux Experiments
XF24 Analyzer (Seahorse Bioscience) was used to measure the change in the oxygen
consumption rate (OCR). Cells were split and seeded with 60,000 cells per well into XF24 cell culture
microplates. Prior to assay, cells were incubated in their respective treatments in a non-CO2 incubator at
37°C for 45 minutes. For the treatments, half of the cell received 30 μl of butyrate at 100mM injected
during assay while the other half received 30 μl glucose free media, and the oxygen consumption rate
(OCR) was measured in pmol/min/cell concentration. The second injection for all cells was 75 μl of 2Deoxy-D-glucose which inhibits glycolysis. Sodium azide was injected last to halt all oxidative
metabolism. OCR data was normalized by Bradford absorbance assay on cell concentration.

3. RESULTS
3.1 Confirmation of PKM2 Knockout in Colorectal Cancer Cells
In order to confirm the success of the knockout of pyruvate kinase M2 (PKM2) in the HCT116
PKM2 Knockout colorectal cancer cells, a Western Blot was performed. Three cell types were used,
HCT116 Wild Type (WT), HCT116 PKM2 mRNA Scramble (Scram), and HCT116 PKM2 Knockout
(KO). The outcome was considered successful if two criteria where met. First, all samples must have
shown a present β-actin control protein band. Second, the WT and Scram cells must have exhibited
bands indicating presence of PKM2 while the PKM2 KO showed no PKM2 band presence. As shown in
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Figure 2, all three cell types exhibited present β-actin and only the HCT116 PKM2 KO cells lacked
PKM2. Therefore, this experiment confirmed the successful knockout of PKM2 in the HCT116 PKM2
KO cells and allowed further experiments to proceed.

HCT116
WT

HCT116
PKM2
Scram

HCT116
PKM2
KO

PKM2

β -Actin

Figure 2: Immunoblot analyses of PKM2 and β-actin from HCT116
WT, HCT116 PKM2 Scramble, and HCT116 PKM2 KO.
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3.2 Schematic of Cellular Metabolism analysis with Mitochondrial Stress Assay
Cellular metabolism of the three cell types was investigated using a The Seahorse XF
Extracellular Flux Analyzer, an instrument that measures oxidative and non-oxidative metabolism. The
three treatments used were as follows: (1) half of the cell wells received 30 μl of butyrate at 100mM
injected during assay while the other half received 30 μl glucose free media, (2) all cells received 75 μ of
2-Deoxy-D-glucose (2DG) which inhibited glycolysis, and (3) all cells received 30 μl sodium azide
which halted all oxidative metabolism. Oxygen consumption rate (OCR) was measured in pmol/min/cell
concentration. Since 2DG inhibits glycolysis, this sequence of treatment injection allowed the
metabolism and OCR of butyrate to be analyzed independently of the other substrates, as shown in
Figure 3. OCR data was normalized based on cell concentration found by Bradford absorbance assay.

OCR (pmol/min/Cell Concentration)

Contribution
to OCR
700.0

Glucose

Glucose
+
Butyrate

Butyrate
Injection

Butyrate

2DG
Injection

Azide
Injection

Area Under Curve
(Butyrate Oxidation)

0.0
0

Time (minutes)

Figure 3: Illustration of rational of Seahorse XF24 Assay. Shading under line shows where butyrate
oxidation will be isolated.
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3.3 Analysis of Metabolism in Response to Butyrate in Three Cell Types
The oxygen consumption rates of HCT116 WT, HCT116 PKM2 KO and HCT116 PKM2 SCR
cells treated with butyrate were analyzed with a mitochondrial stress assay. In the results, all three cell
types began with a basal OCR of ~300 - 420 pmol/min/cell concentration (Fig. 4). When treated with 30
μl butyrate, the oxygen consumption rate of all three cell types increased (Fig. 4). When treated with 75
μl 2-Deoxy-D-glucose (2DG), the OCR of the HCT116 WT cells decreased while the OCR of the
HCT116 PKM2 KO and HCT116 PKM2 SCR cells continued to increase (Fig. 4). The Azide injection
resulted in a sharp decrease in oxygen consumption and halt of metabolism. Figure 5 shows the
maximum OCR of only the area under the curve between injections 2 (2DG) and 3 (Azide) which was
earlier demonstrated to contain only OCR from butyrate oxidation. Results show (Fig. 5-a) HCT116 WT
butyrate oxidation maximum OCR ~250 pmol/min/cell concentration, (Fig. 5-b) HCT116 PKM2 KO
butyrate oxidation maximum OCR ~325 pmol/min/cell concentration, and (Fig. 5-c) HCT 116 PKM2
Scramble butyrate oxidation maximum OCR ~350 pmol/min/cell concentration (Fig. 5).
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Azide

2DG

Butyrate

Figure 4: Change in oxygen consumption (OCR) in HCT116 cells with PKM2 (WT) and without PKM2 (KO)
treated with injection of butyrate. Isolated contribution of butyrate metabolism to OCR is observed after
injection of 2DG.
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Figure 5: Maximum oxygen consumption (OCR) from oxidation of butyrate in HCT116 cells with PKM2 (WT)
and without PKM2 (KO) after treated with injection of butyrate and 2DG.
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3.4 Analysis of Metabolism in Response to Butyrate or Media in Two Cell Types
Additionally, OCR of HCT116 WT and HCT116 PKM2 KO treated with (+) and without (-)
butyrate were directly analyzed against each other. It was notable that the basal OCR of HCT116 WT (-)
butyrate was much higher than the basal OCR of HCT116 WT (+) butyrate, likely caused by
inconsistent cell numbers in the different wells.
Results showed that after the first injection of butyrate, the OCR of HCT116 PKM2 KO (+)
BUT and HCT116 WT (+) BUT increased slightly (Fig. 6). The same cell types treated with glucose
free media maintained their basal OCR and saw no increase upon treatment. Once Treated with 2DG,
the HCT116 WT cells with and without butyrate showed a similar trend of a rapid increase of OCR
followed by a sharp drop in OCR to below their respective basal OCR values (Fig. 6). In contrast, once
treated with 2DG, the HCT116 PKM2 KO cells with and without butyrate showed a steady increase in
OCR until Azide was added.
The oxidation of butyrate is further investigated in figure 7 which compares the OCR after 2DG
injection, measuring either butyrate metabolism, or the metabolism in the absence of butyrate, in the
four conditions. The maximum OCR of HCT116 WT without butyrate (Fig. 7-a) after the 2DG injection
is higher than the maximum OCR of HCT116 WT with butyrate (Fig. 7-b), although this is likely the
result of difference in cell number between the two wells. Interestingly, the maximum OCR after the
2DG injection in HCT116 PKM2 KO cells with butyrate (Fig. 7-d) was higher than the maximum OCR
in HCT116 PKM2 KO cells without butyrate (Fig. 7-c). This is consistent with cells utilizing butyrate
when glucose utilization is inhibited by 2DG.
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Figure 6: Change in oxygen consumption (OCR) in four conditions: HCT116 WT (-) butyrate, HCT116
WT (+) butyrate, HCT116 PKM2 KO (-) butyrate, and HCT116 PKM2 KO (+) butyrate. Isolated
contribution of butyrate metabolism to OCR is observed after injection of 2DG.
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Figure 7: Maximum consumption (OCR) from oxidation of butyrate in HCT116 WT (-) butyrate, HCT116
WT (+) butyrate, HCT116 PKM2 KO (-) butyrate, and HCT116 PKM2 KO (+) butyrate. Isolated
contribution of butyrate metabolism to OCR is observed after injection of 2DG.
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4. Discussion
The effect of PKM2 on cellular metabolism of butyrate in the cancerous colonocyte has not been
investigated in detail. While non-cancerous colonocytes utilize butyrate as a primary energy source,
cancerous colonocytes shift towards an elevated glycolysis to supply their rapid energy needs with
glucose (Delbeke and Martin, 2011; van Kouwen et al., 2006). PKM2 increases the capacity of
cancerous colonocytes to use glucose for energy, and may represent a targetable mechanism of cancer
growth progression.
In this study, we measured metabolic response to removal of PKM2 and subsequent stimulation
by butyrate in live HCT116 colorectal cancer cells. The difference in metabolism trends of colonocytes
containing pyruvate kinase M2 and lacking pyruvate kinase M2 suggest that this enzyme is indeed a
contributing factor to the fate of butyrate in the cell. It was shown that cancer cells that expressed
PKM2, and were likewise driven by glycolysis for energy, exhibited a decrease in oxygen consumption
when treated with butyrate (Fig. 4). This showed that these cells were not readily using butyrate as an
energy source since they normally were driven by glycolysis via PKM2. In contrast, cancer cells that
lacked PKM2 actually increased their oxygen consumption when treated with butyrate (Fig. 4). This
increase in oxygen consumption was likely the result of the cell’s ability to undergo β-oxidation/TCA
cycle and use the butyrate for energy. This supported the proposed hypothesis that removing PKM2
from a cancerous colonocyte plays a role in shifting its metabolism from a cancerous, glycolysis driven
metabolism, to a non-cancerous β-oxidation driven metabolism.
These results were confirmed by comparing the metabolism of cancerous colonocytes with and
without PKM2 when treated with butyrate or glucose free-media (Fig. 6). In both treatments, the cells
expressing PKM2 showed a sharp decrease in oxygen consumption. This finding agreed with the first
experiment and showed that these cells do not readily use butyrate for energy. In contrast, the cells
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lacking PKM2 showed a steady increase in oxygen consumption when treated with butyrate or glucose
free media, with a higher increase in the butyrate treatment. This again showed that cancerous
colonocytes that lack PKM2 exhibit a shift towards non-cancerous metabolism by readily using butyrate
as a primary energy source.

5. Conclusion and Future Work
In conclusion, these findings supported the proposed hypothesis that butyrate cannot be used
efficiently when the Warburg effect is occurring (PKM2 present) and therefore normal colorectal cancer
cells cannot oxidize butyrate efficiently. The findings also support that colorectal cancer cells that lack
PKM2 and lack the Warburg effect are better able to oxidize butyrate as an energy source, and showed a
shift towards non-cancerous metabolism by readily using butyrate as a primary energy source. It was not
determined how this would affect cancerous growth patterns and proliferation.
This research identified a novel mechanism to control the metabolic activity of colorectal cancer
cells in response to butyrate, and could potentially be applied in therapeutic cancer treatment to inhibit
colorectal cancer progression in the future. These finding warrant further research to determine the
effect of butyrate and PKM2 on the growth and metastasis of colorectal cancer cells, as well as further
research to confirm and challenge these results.
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